Company Profile
Biolase Stock Price, News & Analysis
- Ticker:
- BIOL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for BIOL.
Company overview
Business overview
Biolase was a medical technology company focused on dental lasers and related oral-health systems. Its business centered on equipment and procedure adoption rather than drug development.
Geographic Base and Sector Classification
Biolase was headquartered in the United States and listed on NASDAQ. It sat in dental medtech rather than biotechnology.
Business Model Characteristics
The company depended on product adoption, dental-office penetration, and equipment sales execution. Investors historically watched commercialization and the health of the dental capital cycle.
Position Within the Biotechnology Landscape
Biolase belongs in the dental-device layer of healthcare. It is not biotech, but it is a technology-driven medical business tied to procedure and product adoption.
Future catalysts
Biolase is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a fresh device milestone. The market is focused on what value remains.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Biolase do?
Biolase was a medical technology company focused on dental lasers and related oral-health systems. Its business centered on equipment and procedure adoption rather than drug development.
On which exchange is BIOL stock listed?
Biolase (BIOL) is associated with NASDAQ, United States, Biopharma.
What is Biolase?
Biolase is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a fresh device milestone.
Which conditions is Biolase targeting with Biolase?
Biolase is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a fresh device milestone.
How does Biolase describe recent progress with Biolase?
Biolase is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a fresh device milestone.
What future catalysts are investors watching for Biolase?
Biolase is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a fresh device milestone. The market is focused on what value remains.